The pharmaceutical advertising landscape stands at a crossroads as bold new regulatory initiatives threaten to upend decades of established marketing practices. This week, the administration announced plans directing the FDA to reconsider the 30...
A seismic shift is underway in pharmaceutical marketing regulation. Yesterday, the FDA fired a warning shot heard across the industry, announcing a massive crackdown on what they’re calling misleading pharmaceutical advertising. With over 3,500...
The pharmaceutical landscape is transforming before our eyes as drug manufacturers respond to the Biden administration’s May 2023 Most Favored Nation (MFN) pricing executive order with unprecedented domestic investment. This watershed moment has...
A quick chat with Medisafe’s Ryan Janvion, Stacey Wasserman and Cathy Zaremba on what to expect at Fierce Pharma Week 2025. Industry leaders discuss how hyper-personalization sets true patient engagement apart from the buzzwords that saturate the...
A seismic shift is underway in pharmaceutical manufacturing. The FDA’s newly unveiled Advanced Manufacturing Technologies Designation Program promises to accelerate reviews for facilities producing drugs and biologics on American soil—potentially...
Regulatory timelines are changing dramatically, and pharmaceutical companies must adapt or risk being left behind. The Biden administration’s pressure on the FDA is yielding concrete results – approval processes that once took 10-12 months are now...
The global pharmaceutical landscape is undergoing a dramatic transformation, with UK pharma feeling the squeeze from US pricing reforms and tariff threats. This episode dives deep into how the 2022 US Inflation Reduction Act has created a domino...
The gap between receiving a prescription and achieving successful treatment outcomes remains one of healthcare’s biggest challenges. In this illuminating conversation with Ryan Janvion, VP of Sales and Partnerships at Medisafe, we explore how...
What happens when the medications patients need simply aren’t available? The answer is playing out right now across healthcare systems worldwide as pharmaceutical supply chains face unprecedented pressures.The pharmaceutical industry stands at a...
Pharmaceutical manufacturing is undergoing a seismic shift, and Amgen’s latest $550 million investment in a cutting-edge biotech research facility in California marks a pivotal moment in this transformation. This bold move signals far more than...